Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Naptumomab estafenatox
Другие языки:

Naptumomab estafenatox

Подписчиков: 0, рейтинг: 0
Naptumomab estafenatox
Fab-superantigen-fusion protein.svg
Schematic image of naptumomab estafenatox.

VH, VL: variable (antigen binding) domains of antibody fragment
CH1, CL: constant domains of antibody fragment

SAg: superantigen SEA/E-120
Monoclonal antibody
Type Fab fragment
Source Mouse
Target 5T4
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C3255H5025N855O1050S18
Molar mass 73513.02 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma and renal cell carcinoma.

Mechanism of action

Chemically, it is a fusion protein consisting of the antigen-binding fragment (Fab) of a monoclonal antibody with the superantigen staphylococcal enterotoxin A (SEA/E-120, "estafenatox"). The Fab binds to 5T4, an antigen expressed by various tumor cells, and the superantigen induces an immune response by activating T lymphocytes.

See also


Новое сообщение